Chugai Pharmaceutical Co Ltd (JP:4519)

:4519

4519

Chugai Pharmaceutical Co

RESEARCH TOOLSreports

Chugai Pharmaceutical Co (4519) Stock Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4519 Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Chugai

Pharmaceutical Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4519 Stock 12 Month Forecast

Average Price Target

¥11,005.00

▲(8.96% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Chugai Pharmaceutical Co in the last 3 months. The average price target is ¥11,005.00 with a high forecast of ¥13,300.00 and a low forecast of ¥9,500.00. The average price target represents a 8.96% change from the last price of ¥10,100.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6346":"¥6,346","13301":"¥13,301","8084.75":"¥8,084.8","9823.5":"¥9,823.5","11562.25":"¥11,562.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥13K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥11K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥10K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6346,8084.75,9823.5,11562.25,13301],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10145,10387.692307692309,10630.384615384615,10873.076923076924,11115.76923076923,11358.461538461539,11601.153846153846,11843.846153846154,12086.538461538461,12329.23076923077,12571.923076923076,12814.615384615385,13057.307692307691,{"y":13300,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10145,10211.153846153846,10277.307692307691,10343.461538461539,10409.615384615385,10475.76923076923,10541.923076923076,10608.076923076924,10674.23076923077,10740.384615384615,10806.538461538461,10872.692307692309,10938.846153846154,{"y":11005,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10145,10095.384615384615,10045.76923076923,9996.153846153846,9946.538461538461,9896.923076923076,9847.307692307691,9797.692307692309,9748.076923076924,9698.461538461539,9648.846153846154,9599.23076923077,9549.615384615385,{"y":9500,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6347.052,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6781.313,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6576.876,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8176.526,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7129.434,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7230.904,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6423.092,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6597.461,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6944.229,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7952.024,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8243,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8802,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10145,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target¥13,300

Average Price Target¥11,005

Lowest Price Target¥9,500

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Macquarie

Not Ranked

Macquarie

¥9,500

Buy

-5.94%

Downside

Reiterated

03/23/26

Macquarie Sticks to Its Buy Rating for Chugai Pharmaceutical Co (CHGCF)

Miki Sogi

Bernstein

¥9,900

Buy

-1.98%

Downside

Reiterated

03/12/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Unknown Analyst

Daiwa

Not Ranked

Daiwa

¥11,000

Buy

8.91%

Upside

Reiterated

03/05/26

Daiwa Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

¥11,750

Buy

16.34%

Upside

Reiterated

03/04/26

Morgan Stanley Sticks to Their Buy Rating for Chugai Pharmaceutical Co (CHGCF)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

¥10,000

Hold

-0.99%

Downside

Reiterated

03/04/26

Mizuho Securities Sticks to Its Hold Rating for Chugai Pharmaceutical Co (CHGCF)

Unknown Analyst

SBI Securities

Not Ranked

SBI Securities

¥12,700

Buy

25.74%

Upside

Reiterated

03/02/26

SBI Securities Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)

Unknown Analyst

SMBC Nikko

Not Ranked

SMBC Nikko

¥9,500→¥10,700

Buy

5.94%

Upside

Reiterated

02/25/26

Chugai Pharmaceutical Co (CHGCF) Receives a Buy from SMBC Nikko

Unknown Analyst

Citi

Not Ranked

Citi

¥13,300

Buy

31.68%

Upside

Reiterated

02/12/26

Chugai Pharmaceutical Co (CHGCF) Gets a Buy from Citi

Seiji Wakao

J.P. Morgan

¥9,500→¥10,700

Buy

5.94%

Upside

Reiterated

02/06/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Unknown Analyst

UBS

Not Ranked

UBS

¥10,500

Buy

3.96%

Upside

Reiterated

01/27/26

UBS Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)

Hiroyuki Matsubara

Nomura

¥6,800→¥6,500

Hold

-35.64%

Downside

Reiterated

08/20/25

Nomura Reaffirms Their Hold Rating on Chugai Pharmaceutical Co (CHGCF)

Stephen Barker

Jefferies

¥8,400

Hold

-16.83%

Downside

Reiterated

04/24/25

Jefferies Keeps Their Hold Rating on Chugai Pharmaceutical Co (CHGCF)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Macquarie

Not Ranked

Macquarie

¥9,500

Buy

-5.94%

Downside

Reiterated

03/23/26

Macquarie Sticks to Its Buy Rating for Chugai Pharmaceutical Co (CHGCF)

Miki Sogi

Bernstein

¥9,900

Buy

-1.98%

Downside

Reiterated

03/12/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Unknown Analyst

Daiwa

Not Ranked

Daiwa

¥11,000

Buy

8.91%

Upside

Reiterated

03/05/26

Daiwa Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

¥11,750

Buy

16.34%

Upside

Reiterated

03/04/26

Morgan Stanley Sticks to Their Buy Rating for Chugai Pharmaceutical Co (CHGCF)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

¥10,000

Hold

-0.99%

Downside

Reiterated

03/04/26

Mizuho Securities Sticks to Its Hold Rating for Chugai Pharmaceutical Co (CHGCF)

Unknown Analyst

SBI Securities

Not Ranked

SBI Securities

¥12,700

Buy

25.74%

Upside

Reiterated

03/02/26

SBI Securities Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)

Unknown Analyst

SMBC Nikko

Not Ranked

SMBC Nikko

¥9,500→¥10,700

Buy

5.94%

Upside

Reiterated

02/25/26

Chugai Pharmaceutical Co (CHGCF) Receives a Buy from SMBC Nikko

Unknown Analyst

Citi

Not Ranked

Citi

¥13,300

Buy

31.68%

Upside

Reiterated

02/12/26

Chugai Pharmaceutical Co (CHGCF) Gets a Buy from Citi

Seiji Wakao

J.P. Morgan

¥9,500→¥10,700

Buy

5.94%

Upside

Reiterated

02/06/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Unknown Analyst

UBS

Not Ranked

UBS

¥10,500

Buy

3.96%

Upside

Reiterated

01/27/26

UBS Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)

Hiroyuki Matsubara

Nomura

¥6,800→¥6,500

Hold

-35.64%

Downside

Reiterated

08/20/25

Nomura Reaffirms Their Hold Rating on Chugai Pharmaceutical Co (CHGCF)

Stephen Barker

Jefferies

¥8,400

Hold

-16.83%

Downside

Reiterated

04/24/25

Jefferies Keeps Their Hold Rating on Chugai Pharmaceutical Co (CHGCF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Chugai Pharmaceutical Co

3 Months

xxx

Success Rate

2/2 ratings generated profit

Average Return

+6.45%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +6.45% per trade.

1 Year

Seiji WakaoJ.P. Morgan

Success Rate

6/6 ratings generated profit

Average Return

+23.70%

reiterated a buy rating 2 months ago

Copying Seiji Wakao's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +23.70% per trade.

2 Years

xxx

Success Rate

6/6 ratings generated profit

Average Return

+29.43%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +29.43% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4519 Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4519 has received 51 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 4519 average Analyst price target in the past 3 months is 11,005.00.

Each month's total comprises the sum of three months' worth of ratings.

4519 Financial Forecast

4519 Earnings Forecast

Next quarter’s earnings estimate for 4519 is ¥63.05 with a range of ¥59.73 to ¥69.33. The previous quarter’s EPS was ¥78.03. 4519 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 4519 has Performed in-line its overall industry.

4519 Sales Forecast

Next quarter’s sales forecast for 4519 is ¥295.33B with a range of ¥283.00B to ¥306.77B. The previous quarter’s sales results were ¥346.30B. 4519 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 4519 has Performed in-line its overall industry.

4519 Stock Forecast FAQ

What is JP:4519’s average 12-month price target, according to analysts?

Based on analyst ratings, Chugai Pharmaceutical Co Ltd’s 12-month average price target is 11,005.00.

What is JP:4519’s upside potential, based on the analysts’ average price target?

Chugai Pharmaceutical Co Ltd has 8.96% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Chugai Pharmaceutical Co Ltd a Buy, Sell or Hold?

Chugai Pharmaceutical Co Ltd has a consensus rating of Strong Buy, which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Chugai Pharmaceutical Co Ltd’s share price target?

The average share price target for Chugai Pharmaceutical Co Ltd is 11,005.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ¥13,300.00 ,and the lowest forecast is ¥9,500.00. The average share price target represents 8.96% Increase from the current price of ¥10,100.

What do analysts say about Chugai Pharmaceutical Co Ltd?

Chugai Pharmaceutical Co Ltd’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of Chugai Pharmaceutical Co Ltd?

To buy shares of JP:4519, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Chugai Pharmaceutical Co (4519) Stock Forecast & Price Target

4519 Analyst Ratings

4519 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Chugai Pharmaceutical Co

4519 Analyst Recommendation Trends

4519 Financial Forecast

4519 Earnings Forecast

4519 Sales Forecast

4519 Stock Forecast FAQ

Detailed List of Analyst Forecasts